Advertisement

Advertisement

ALPMF Stock Latest News

Astellas Books Major Impairment and Extraordinary Losses in FY2025 Non-Consolidated Results

Company AnnouncementsAstellas Books Major Impairment and Extraordinary Losses in FY2025 Non-Consolidated Results

Astellas Pharma Announces New Board Slate and Governance Changes for 2026

PremiumCompany Announcements

Astellas Pharma Announces New Board Slate and Governance Changes for 2026

2d ago

Is ALPMF a Buy, Before Earnings?

PremiumPre-Earnings

Is ALPMF a Buy, Before Earnings?

4d ago

Astellas’ Menopause Drug Fezolinetant Hits Key Safety Milestone in Japan

PremiumCompany Announcements

Astellas’ Menopause Drug Fezolinetant Hits Key Safety Milestone in Japan

21d ago

Astellas Highlights R&D Strategy While Flagging Market and Development Risks

PremiumCompany Announcements

Astellas Highlights R&D Strategy While Flagging Market and Development Risks

29d ago

Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal

PremiumCompany AnnouncementsAstellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal

2M ago

Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline

Company Announcements

Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline

2M ago

Why Is Vir Biotechnology Stock Up Today?

Market News

Why Is Vir Biotechnology Stock Up Today?

2M ago

Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus

PremiumCompany Announcements

Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus

3M ago

Astellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion

PremiumCompany Announcements

Astellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion

3M ago

Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold

PremiumRatings

Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold

3M ago

Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand

PremiumCompany Announcements

Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand

3M ago

ALPMF Upcoming Earnings Report: What to Expect?

PremiumPre-EarningsALPMF Upcoming Earnings Report: What to Expect?

3M ago

Astellas Targets Post‑Stroke Recovery With First‑in‑Human ASP2246 Study

Company Announcements

Astellas Targets Post‑Stroke Recovery With First‑in‑Human ASP2246 Study

4M ago

Astellas Completes Key Menopause Drug Study in Japan, Setting Up Next Growth Phase for Fezolinetant

Company Announcements

Astellas Completes Key Menopause Drug Study in Japan, Setting Up Next Growth Phase for Fezolinetant

4M ago

Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment

PremiumCompany Announcements

Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment

4M ago

Astellas Pharma Revises FY2025 Financial Forecasts Upward

PremiumCompany Announcements

Astellas Pharma Revises FY2025 Financial Forecasts Upward

6M ago

Astellas Pharma (ALPMF) Q2 Earnings Cheat Sheet

PremiumPre-Earnings

Astellas Pharma (ALPMF) Q2 Earnings Cheat Sheet

6M ago

Astellas Pharma’s ASP4396 Study: A Potential Game-Changer for Solid Tumors

PremiumCompany Announcements

Astellas Pharma’s ASP4396 Study: A Potential Game-Changer for Solid Tumors

6M ago

Astellas Pharma’s ASP3021 Study: A New Hope for AMD Patients?

PremiumCompany AnnouncementsAstellas Pharma’s ASP3021 Study: A New Hope for AMD Patients?

6M ago

Astellas Pharma’s Peficitinib Study: Key Insights for Investors

Company Announcements

Astellas Pharma’s Peficitinib Study: Key Insights for Investors

6M ago

Astellas Pharma’s Innovative Bladder Device: A Game Changer in Urinary Health?

Company Announcements

Astellas Pharma’s Innovative Bladder Device: A Game Changer in Urinary Health?

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >